close

Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology

Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology Collaboration combines Intellia’s proprietary genome editing technology platform with SparingVision’s significant ophthalmology expertise Intellia will grant SparingVision exclusive rights to its leading in vivo CRISPR/Cas9 technology for the development of ocular therapies directed to three…..

Boehringer Ingelheim to expand veterinary vaccine capacity for emerging and transboundary diseases in France

Boehringer Ingelheim to expand veterinary vaccine capacity for emerging and transboundary diseases in France Boehringer Ingelheim announced an additional €100 million investment in its veterinary public health capabilities in Lyon-Jonage, France, to aid governments and public health organizations in managing future emerging and transboundary diseases. Transboundary and emerging diseases are…..

License Option Agreement with Pfizer for Voyager Therapeutic’s Next-Generation TRACERᵀᴹ AAV Capsids

License Option Agreement with Pfizer for Voyager Therapeutic's Next-Generation TRACERᵀᴹ AAV Capsids Voyager Therapeutics, a gene therapy company developing adeno-associated virus (AAV) platform technologies, announced an agreement through which Pfizer may exercise options to license novel capsids generated from Voyager’s RNA-driven TRACERTM (Tropism Redirection of AAV by Cell-type-specific Expression of…..

Envisagenics Raises Series A Financing to Scale Its AI-powered RNA Splicing Drug Discovery Platform

Envisagenics Raises Series A Financing to Scale its AI-powered RNA Splicing Drug Discovery Platform Envisagenics, an Artificial Intelligence-driven biotechnology company focused on the discovery and development of novel RNA splicing therapeutics, secured Series A financing to scale its drug discovery platform and biopharmaceutical partnerships. Red Cell Partners led the financing,…..